Results 1 to 10 of about 181,578 (308)

The Chimeric Antigen Receptor Detection Toolkit [PDF]

Frontiers in Immunology, 2020
Chimeric antigen receptor-T (CAR-T) cell therapy is a promising frontier of immunoengineering and cancer immunotherapy. Methods that detect, quantify, track, and visualize the CAR, have catalyzed the rapid advancement of CAR-T cell therapy from ...
Yifei Hu, Yifei Hu, Jun Huang
doaj   +3 more sources

A TCR-based Chimeric Antigen Receptor [PDF]

Scientific Reports, 2017
Effector T cells equipped with engineered antigen receptors specific for cancer targets have proven to be very efficient. Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (TCR) redirection.
Even Walseng, Hakan Köksal, Ibrahim M. Sektioglu, Anne Fåne, Gjertrud Skorstad, Gunnar Kvalheim, Gustav Gaudernack, Else Marit Inderberg, Sébastien Wälchli   +8 more
doaj   +3 more sources

Chimeric Antigen Receptor-T Cell Therapy [PDF]

HemaSphere, 2018
. Chimeric antigen receptor (CAR)-T cell therapy is a new class of cellular immunotherapies that involves ex vivo genetic modification of T cells to incorporate an engineered CAR.
Jochen Buechner, Marie José Kersten, Miriam Fuchs, Florence Salmon, Ulrich Jäger   +4 more
doaj   +3 more sources

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation

Frontiers in Immunology, 2022
Co-stimulation is critical to the function of chimeric antigen receptor (CAR) T-cells. Previously, we demonstrated that dual co-stimulation can be effectively harnessed by a parallel (p)CAR architecture in which a CD28-containing second generation CAR is
Leena Halim, Kushal K. Das, Daniel Larcombe-Young, Adam Ajina, Andrea Candelli, Reuben Benjamin, Reuben Benjamin, Richard Dillon, Richard Dillon, David M. Davies, John Maher, John Maher, John Maher, John Maher   +13 more
doaj   +1 more source

Engineering Chimeric Antigen Receptors [PDF]

Acta Naturae, 2017
Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens.
S V, Kulemzin, V V, Kuznetsova, M, Mamonkin, A V, Taranin, A A, Gorchakov   +4 more
openaire   +2 more sources

Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens

Nature Communications, 2021
Chimeric antigen receptor T cells in the clinic currently target cell-type-specific extracellular antigens on malignant cells. Here, authors engineer tumor-specific chimeric antigen receptor T cells that target human leukocyte antigen-presented ...
Michael S. Hwang, Michelle S. Miller, Puchong Thirawatananond, Jacqueline Douglass, Katharine M. Wright, Emily Han-Chung Hsiue, Brian J. Mog, Tihitina Y. Aytenfisu, Michael B. Murphy, P. Aitana Azurmendi, Andrew D. Skora, Alexander H. Pearlman, Suman Paul, Sarah R. DiNapoli, Maximilian F. Konig, Chetan Bettegowda, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Shibin Zhou, Sandra B. Gabelli   +21 more
doaj   +1 more source

Posttransplant chimeric antigen receptor therapy [PDF]

Blood, 2018
Abstract Therapeutic T-cell engineering is emerging as a powerful approach to treat refractory hematological malignancies. Its most successful embodiment to date is based on the use of second-generation chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule found in most B-cell leukemias and lymphomas.
Melody Smith, Johannes Zakrzewski, Scott James, Michel Sadelain   +3 more
openaire   +2 more sources

Next-Generation Chimeric Antigen Receptor T-cells

Hematology/Oncology and Stem Cell Therapy, 2022
The U.S. Food and Drug Administration (FDA) approved 6 CAR T cell (CAR-T) products, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), idecabtagene ...
Dongni Yi, Mia Gergis, Jingmei Hsu, Yang Yang, Xia Bi, Mahmoud Aljurf, Usama Gergis   +6 more
doaj   +1 more source

Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives

ImmunoMedicine, 2022
Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B‐cell malignancies, many studies ...
Yue Huang, Mi Shao, Yiyun Wang, He Huang
doaj   +1 more source

Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. [PDF]

, 2020
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in the treatment of haematological cancers and is currently being investigated for solid tumours, including high-grade glioma brain tumours.
Abler, Daniel, Adhikarla, Vikram, Barish, Michael, Branciamore, Sergio, Brown, Christine E, Cho, Heyrim, Frankhouser, David, Gutova, Margarita, Machuca, Vanessa, Maestrini, Davide, Rockne, Russell C, Sahoo, Prativa, Wang, Dongrui, Yang, Xin   +13 more
core   +2 more sources